Entries by Ayal Ronen

Webinar: U Mechanisms, cooperative agreements with the NIH

The U-Mechanism is a support mechanism used when there will be substantial Federal scientific or programmatic involvement by granting agency. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities. We are seeing many programs utilizing this type of mechanism, with substantial awards being made to […]

Webinar: Non-Dilutive funding for Non-US applicants

Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations […]

FreeMind is Proud to Support the RESI Conference on September 16th – Boston

Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) are inviting fundraising life science companies to attend the upcoming Redefining Early Stage Investments (RESI) Conference in Boston on September 16th.   The first RESI Conference took place on September 16, 2013, and two years later, following highly successful events in San Francisco and Houston, LSN returns to Boston for the sixth […]

Funding beyond the SBIR/STTR; RO1s and R21s for Companies

Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources. R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas […]

SBIR STTR Funding; Driving Innovation through Non Dilutive Sources

SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone to industry. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, […]

Come meet FreeMind at our booth at BIO – Booth 4259

Come say hello at our booth at the Bio International Convention taking place in Philadelphia – June 15 – 18, 2015. Ram May-Ron, Managing Partner, FreeMind Group and Guy-Har-Chen, FreeMind’s Chief Analyst will be taking meetings throughout the day in the booth. Come by for an Espresso, or drop your card to win a giant whiskey! (3.5L […]

Press Release: Spotlight Innovation Subsidiary Celtic Biotech Retains the FreeMind Group to Identify, Prepare, and File for Research and Development Grant Opportunities

Spotlight Innovation Inc. (OTCQB: STLT) announces today that FreeMind Group LLC has been retained by its subsidiary Celtic Biotech Iowa, Inc. to identify grant and contract funding opportunities from such agencies as the National Institutes of Health (NIH), Department of Defense (DoD) and Private Foundations, and to prepare and file grant applications for relevant opportunities. […]

April 27 – Cambridge, MA: Presentations by the FreeMind Group, Life Science Nation and Jameson & Company

           Presentations by the FreeMind Group, Life Science Nation and Jameson & Company Boston Cambridge Marriott – 50 Broadway, Cambridge, MA April 27th, 2015   Join the FreeMind Group, LSN and Jameson and Company for a day of educational programing for life science executives on the topics of non-dilutive funding and post […]